Algo version: 0.98b
Cosmo Pharmaceuticals NV is listed at the LSE Exchange
Cosmo Pharmaceuticals NV [0RGI.L]
LSE Sector: Healthcare Industry:Medical Pharmaceuticals

Is Cosmo Pharmaceuticals NV stock a buy?

What Is The Conclusion?

Right now our advanced algorithms say:

Do the analyst corps agree?

Interesting Questions and Easy Answers!

Yes, Cosmo Pharmaceuticals NV pays dividends. Last time was Friday 12th of July 2024 where the investors holding the stock on Wednesday 10th of July 2024 were paid CHF1.94195 per share. Over the last 4 times between 2016 and 2024, Cosmo Pharmaceuticals NV has paid CHF7.00466 with an average of CHF1.75 per share.

Sorry, we do not have any analyst data for this ticker

We cannot find data for Cosmo Pharmaceuticals NV 10 years ago, but if you had invested on Friday 22nd of November 2019 when the price was CHF70.50, you would have made a loss of CHF-8.40 per share or -11.91%

No, the average daily trading liquidity for Cosmo Pharmaceuticals NV is CHF1 442 thousand. Trading in stocks with this little trading liquidity is very dangerous, and you can get into a situation where it will be hard to trade your stocks. In addition, these types of stocks usually have very high volatility.

Cosmo Pharmaceuticals NV has no real debt, which is good in periods of high inflation. With a high cash flow to debt ratio of 209.89, the company's ability to pay off the debt is good. Cosmo Pharmaceuticals NV has a very good net profit margin of 37.53% and should have very high tolerances against inflation.

We have calculated the inflation risk for Cosmo Pharmaceuticals NV to be low [0 of 1]

US inflation for August 2024 was 0.19%. Over the last 12 months, the US inflation is 2.59%. The 10-year treasury yield that indicates the future interest level is currently 4.41 and is up 0.05 over the last 30 days.